Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Blastic Plasmacytoid Dendritic Cell Neoplasm

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Blastic Plasmacytoid Dendritic Cell Neoplasm

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 4 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      4 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT02113982 · Source cited / selected · Scope: narrower

      Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

      6 outcome links · 14 safety-group records · 0 quality-of-life measures

      →

      NCT03075553 · Registry condition search · Scope: narrower

      Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03246906 · Registry condition search · Scope: narrower

      Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT03386513 · Source cited / selected · Scope: narrower

      Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

      6 outcome links · 11 safety-group records · 0 quality-of-life measures

      →

      Indication-specific source history

      Dated source events, not confirmation of current approval for every use of a drug.

      2026-05-27 · pivekimab sunirine-pvzy · approval notification
      release id
      clinical-indications-draft-1
      disease state id
      ds-blastic-plasmacytoid-dendritic-cell-neoplasm
      event id
      notice-3a7bfc201292d867
      event date
      2026-05-27
      event kind
      approval-notification
      drug or regimen
      pivekimab sunirine-pvzy
      source indication text
      FDA approved pivekimab sunirine-pvzy, a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm .
      match phrase
      blastic plasmacytoid dendritic cell neoplasm
      match status
      candidate
      status category
      Source null
      has date discrepancy
      0
      source collection
      fda-approval-notice
      source key
      fda-d96394837965add4
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-blastic-plasmacytoid-dendritic-cell-neoplasm
        binding id
        ncit-C7203
        source collection
        ncit-concept
        source key
        C7203
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice